ProMIS Neurosciences, Inc. (PMN)
NASDAQ: PMN · Real-Time Price · USD
1.366
+0.066 (5.09%)
Aug 30, 2024, 4:00 PM EDT - Market closed
ProMIS Neurosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
7
Market Cap
40.83M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
NeueHealth | 1.03B |
Inotiv | 501.06M |
electroCore | 21.28M |
Dyadic International | 1.80M |
Daxor | 154.21K |
PMN News
- 4 weeks ago - ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024 - GlobeNewsWire
- 4 weeks ago - ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference - GlobeNewsWire
- 5 weeks ago - ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial - GlobeNewsWire
- 5 weeks ago - ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing - GlobeNewsWire
- 3 months ago - ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights - GlobeNewsWire
- 4 months ago - ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies - GlobeNewsWire
- 5 months ago - ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS - GlobeNewsWire
- 5 months ago - ProMIS Neurosciences to Present in Upcoming Investor Conferences in April - GlobeNewsWire